Friday, June 24, 2011 10:21:46 AM
ROBERTO PLEASE TAKE NOTICE,
I am of the opinion that by now CGAQ has realized that continuing
with press releases that have exaggerations are hurting the share
price. The " First letter of Approval " is by now out of the way and
we realize what is happening. As I see it the only stumbling block
left is CGAQ's refusal to clarify the number of slot machines that
are presently installed at Puerto Plata.
If the present number is less than 100, the number originally planned
to be installed, so what. A business decision was made and the slots
are been installed where they are most profitable. Just give us the number
for those who are interested in knowing, which includes me.
Don't wait until the 100 are finally in. The delay is causing CGAQ's
truthfulness to be questioned and rightly so.
CGAQ with the coming boxing matches has too much going for it
for it to be delaying over something that is really insignificant in the
scheme of things, or so the situation seems to me.
I said it before and I will say it again, to me the money that CGAQ can
make in the boxing arena is enough by itself to make it a much higher
price stock.
I am of the opinion that by now CGAQ has realized that continuing
with press releases that have exaggerations are hurting the share
price. The " First letter of Approval " is by now out of the way and
we realize what is happening. As I see it the only stumbling block
left is CGAQ's refusal to clarify the number of slot machines that
are presently installed at Puerto Plata.
If the present number is less than 100, the number originally planned
to be installed, so what. A business decision was made and the slots
are been installed where they are most profitable. Just give us the number
for those who are interested in knowing, which includes me.
Don't wait until the 100 are finally in. The delay is causing CGAQ's
truthfulness to be questioned and rightly so.
CGAQ with the coming boxing matches has too much going for it
for it to be delaying over something that is really insignificant in the
scheme of things, or so the situation seems to me.
I said it before and I will say it again, to me the money that CGAQ can
make in the boxing arena is enough by itself to make it a much higher
price stock.
Recent BSEM News
- BioStem Technologies to Showcase Innovation and Clinical Evidence at Symposium on Advanced Wound Care Spring 2026 • GlobeNewswire Inc. • 04/08/2026 11:00:00 AM
- BioStem Technologies to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/31/2026 08:05:00 PM
- BioStem Technologies Announces the Publication of its Audited Financial Statements for Fiscal Years 2024 and 2025 • GlobeNewswire Inc. • 03/30/2026 11:00:00 AM
- BioStem Technologies Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 03/24/2026 08:05:00 PM
- BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair • GlobeNewswire Inc. • 03/23/2026 03:40:56 PM
- BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair • GlobeNewswire Inc. • 03/23/2026 11:00:00 AM
- BioStem Technologies to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 24, 2026 • GlobeNewswire Inc. • 03/11/2026 08:05:00 PM
- BioStem Technologies to Present at the 46th Annual TD Cowen Healthcare Conference • GlobeNewswire Inc. • 02/20/2026 12:00:00 PM
- BioStem Technologies Highlights Alignment with FDA’s Openness to Bayesian Statistical Approaches in Clinical Research • GlobeNewswire Inc. • 02/03/2026 09:05:00 PM
- BioStem Technologies Advances Entry into the Acute Wound Care Market with Acquisition of BioTissue Holdings’ Surgical and Wound Care Business • GlobeNewswire Inc. • 01/21/2026 10:30:00 PM
- BioStem Technologies Comments on Withdrawal of CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes • GlobeNewswire Inc. • 01/07/2026 09:05:00 PM
- BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes • GlobeNewswire Inc. • 12/18/2025 12:00:00 PM
- BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference • GlobeNewswire Inc. • 12/10/2025 12:00:00 PM
- BioStem Technologies Expands Product Access in Medicaid • GlobeNewswire Inc. • 11/25/2025 01:59:13 PM
- BioStem Technologies Reports Third Quarter 2025 Financial Results • GlobeNewswire Inc. • 11/13/2025 09:02:00 PM
- BioStem Technologies Announces Filing of Restated Financial Statements • GlobeNewswire Inc. • 11/13/2025 09:01:00 PM
- BioStem Technologies Provides Comments on CMS CY 2026 Final Medicare Reimbursement Rule Changes for Skin Substitutes • GlobeNewswire Inc. • 11/05/2025 09:05:00 PM
- BioStem Technologies Secures Land Purchase at the Research Park at Florida Atlantic University in Boca Raton for Future Headquarters • GlobeNewswire Inc. • 11/05/2025 12:00:00 PM
- BioStem Technologies Reports Positive Top-Line Clinical Results Demonstrating Superior Outcomes with BioRetain® Allograft in Diabetic Foot Ulcers • GlobeNewswire Inc. • 10/31/2025 11:00:00 AM
- BioStem Technologies to Host Third Quarter 2025 Financial Results Conference Call on November 13, 2025 • GlobeNewswire Inc. • 10/30/2025 08:05:00 PM
- BioStem Technologies Appoints KPMG as its Independent Registered Public Accountant • GlobeNewswire Inc. • 10/27/2025 08:15:00 PM
- BioStem Technologies Expands Partnership with the Florida Panthers as a Sponsor for the 13th Season of the “Heroes Among Us” Program • GlobeNewswire Inc. • 10/02/2025 04:00:00 PM
